Abbott (NYSE:ABT) announced today that the FDA approved the longer length (76 mm) Esprit BTK drug-eluting scaffold system. The longer Esprit BTK system received approval for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD). CLTI can cause extreme pain, open wounds that don’t heal and, in some cases, […]
Drug-Device Combinations
FDA approves Sanofi anticancer treatment delivered through Enable Injections on-body device
Sanofi announced today that the FDA approved the delivery of its Sarclisa anticancer therapy through the Enable Injections on-body device. Sarclisa (isatuximab-irfc) Escena in combination with standard-of-care regimens received clearance for the treatment of patients with multiple myeloma (MM) across all existing indications of the Sarclisa intravenous (IV) formulation. Approval makes it the first anticancer […]
ViCentra Kaleido with G7, DBLG2 algorithm now available in Germany
Diabeloop announced today that its DBLG2 automated insulin delivery algorithm is now open for prescription with Dexcom G7 and ViCentra Kaleido. The companies now offer their integrated automated insulin delivery system in Germany, with availability to come in the Netherlands soon. Their updated system combines the company’s Kaleido patch pump with Diabeloop’s DBLG2 algorithm and the Dexcom G7 continuous glucose […]
Otsuka ICU Medical to invest $500M in IV solutions manufacturing in the US
Otsuka ICU Medical today announced plans to invest more than $500 million to expand its U.S. IV solutions manufacturing in Texas. The companies (Otsuka Pharmaceutical Factory and ICU Medical), which launched this joint venture last year, plan to deliver a new facility and significant upgrades to its existing operations in Austin, Texas. They expect the […]
Vivani, Novo Nordisk partner to evaluate long-term semaglutide implant
Vivani Medical (Nasdaq:VANI) today announced a new agreement with Novo Nordisk to evaluate the NPM-139 long-term semaglutide implant. NPM-139 utilizes the Alameda, California-based company’s NanoPortal platform technology, under development for chronic weight management. Vivani designed NanoPortal technology to steadily deliver medication over extended periods of time. The company aims to guarantee correct doses for patients while […]
Insulet launches Omnipod 5, Omnipod Discover in Spain
Insulet (Nasdaq:PODD) announced today that it launched its Omnipod 5 insulin pump and Omnipod Discover platform in Spain. With the launch, Spain becomes the 26th country in which Insulet sells Omnipod and the 20th reached by Omnipod 5, the company’s latest-generation patch-based automated insulin delivery system. Omnipod 5 became the world’s first available tubeless, wearable, […]
West completes sale of on-body drug delivery device to AbbVie
West Pharmaceutical Services (NYSE:WST) announced that it completed the sale of its SmartDose on-body delivery system to AbbVie. Exton, Pennsylvania-based West sold and transferred its manufacturing and supply rights for the SmartDose 3.5mL on-body delivery system and associated facilities to AbbVie. The companies closed their transaction, as planned, on July 1, 2026. West will continue […]
Tandem Diabetes Care launches t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in new geographies
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it launched the t:slim X2 insulin pump with the Abbott FreeStyle Libre 3 Plus in five new countries. San Diego-based Tandem launched the pairing of its flagship automated insulin delivery system with Control-IQ+ technology with Abbott’s latest continuous glucose monitor (CGM) sensor in the U.S. in October 2025. […]
BD names new president of Pharmacy Automation biz
BD (NYSE:BDX) announced today that it appointed Matthew Sassone as worldwide president of its Pharmacy Automation business. Sassone now leads the global business within the BD Medication Management Solutions business unit. His appointment goes into effect immediately. In the role, Sassone’s responsibilities include driving global strategy, performance and growth for Pharmacy Automation as part of […]
Terrestrial Bio doses first patients in GLP-1 patch trial
Terrestrial Bio announced today that it dosed the first patients in a Phase I clinical trial evaluating its patch that delivers GLP-1 therapeutic semaglutide. Boston-based Terrestrial (formerly Vaxess Technologies) is evaluating VX-201, a needle-free microarray patch (MAP) in the trial. The company designed its MAP technology features a soluble microarray with tips that gradually dissolve into […]
